Emergent BioSolutions Inc EBS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
-
Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
-
Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
-
EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law
-
Emergent BioSolutions (EBS) Securities Investigation Notice - Levi & Korsinsky
Trading Information
- Previous Close Price
- $6.37
- Day Range
- $6.24–6.41
- 52-Week Range
- $4.36–14.06
- Bid/Ask
- $6.17 / $6.34
- Shares Outstanding
- 51.27M
- Market Cap
- $324.56M
- Volume/Avg
- 614,590 / 1M
Key Statistics
- Price/Earnings (Normalized)
- 4.34
- Price/Sales
- 0.47
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 11.09%
Company Profile
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 900
Valuation
|
Metric
|
EBS
|
|---|---|
Price/Earnings (Normalized) | 4.34 |
Price/Book Value | 0.96 |
Price/Sales | 0.47 |
Price/Cash Flow | 1.99 |
Price/Earnings
EBS
Financial Strength
|
Metric
|
EBS
|
|---|---|
Quick Ratio | 1.90 |
Current Ratio | 4.29 |
Interest Coverage | −1.87 |
Quick Ratio
EBS
Profitability
|
Metric
|
EBS
|
|---|---|
Return on Assets (Normalized) | 6.07% |
Return on Equity (Normalized) | 16.06% |
Return on Invested Capital (Normalized) | 10.85% |
Return on Assets
EBS
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|Sq??r^b | LOCK|@v^D | $67B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|D%x#@h$ | LOCK|<n$y! | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|^dvpc? | LOCK|!rM | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|Z<^fN!K# | LOCK|?< | $29B | |||
| Viatris Inc
VTRS
| LOCK|>vbDZn | LOCK|Yy< | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|Bt$ | LOCK|N! | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|cNFT%@ | LOCK|!@! | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|!HS@N>P | LOCK|%Gf | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|w^gL@< | LOCK|LgBC | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|F!jr!< | LOCK|&Xj | $2B |
United States